10.06.26 -- Strategic CDMO Partnerships: From Vendor To Collaborative Partner

Design-of-experiment methodology accelerates cell therapy assay development, reducing costs and timelines while improving assay robustness, regulatory readiness, and data-driven decision-making.

Enzymatically synthesized DNA is assessed as a plasmid alternative, showing comparable viral vector yield, quality, and purification, while improving scalability and regulatory flexibility.

Choosing the right CDMO requires early internal assessment plus strong technical capability, agility, advocacy, clear communication, and long‑term alignment to meet evolving cell and gene therapy needs.

Redundant requalification tasks can delay late-stage clinical expansion. Standardized protocols reduce repeat validation, lower costs, maintain quality, and support commercialization.

Accelerate access to high-quality, cost-effective lentiviral vectors with our manufacturing platform, delivering multi-fold yield improvements and scalable, space-efficient production.

De-risk genetic medicine development with a phased evaluation approach. Gain rapid, data-driven feasibility insights before major investments, enabling smarter decisions and faster clinical progress.

Biotech visibility improves through real-time data and centralized platforms, enabling collaboration, faster decisions, reduced risk, and better partner alignment.

GLP compliance isn’t binary. Real defensibility depends on rigorous QA, validated electronic systems, and operational maturity — not just a label.

Standard platform processes promise speed and consistency in CGT development, but biological variability and evolving program needs often expose their limitations.

Standardized point-of-care manufacturing overcomes cell therapy access, cost, and supply challenges, enabling regional centers to efficiently deliver high-quality treatments.

Discover how a microbubble cell separation system outperformed standard magnetic methods in T cell recovery, speed, and scalability — achieving higher cell quality with innovative microbubble technology.

Learn how lentiviral vector processes evolve for in vivo and ex vivo CAR‑T—covering yield, purity, scalability, and shifting regulatory demands for safe, consistent systemic delivery.

Uncover the secrets behind successes in commercializing and producing commercial cell and gene therapies, including establishing standards of every day, manufacturing operational excellence.